Pharmaceutical News

RSS

Macomb County Health Department opens new H1N1 influenza immunization clinics

Sfter holding more than a dozen H1N1 influenza immunization clinics this fall targeting people in high-risk groups, the Macomb County Health Department announced today that it is opening its upcoming clinics to everyone 6 months of age and older.

9 Dec 2009

Neuroscientists suggest risky therapy for aging brain may be avoidable by focusing on hormone target

Estrogen seems to act like a middleman in its positive effect on the brain, raising the possibility that future drugs may bypass the carcinogenic hormone altogether while reaping its benefits.

8 Dec 2009

Scientists identify new potential drug for treating acute myeloid leukaemia

EUREKA project E! 3172 NKSTIM has produced a new potential drug to stimulate cancer patients' own 'natural killer' cells to attack and eliminate cancer cells; currently undergoing clinical testing in patients with leukaemia or myeloma.

8 Dec 2009

CDC awards $19.7 million contract to study new drugs for tuberculosis treatment

John L. Johnson, M.D., Professor of Medicine at Case Western Reserve University School of Medicine and pulmonologist at University Hospitals Case Medical Center has been awarded a 10 year, $19.7M contract from the U.S. Centers for Disease Control and Prevention (CDC) as an international clinical trials site for the Tuberculosis Trials Consortium (TBTC).

8 Dec 2009

House Democrats criticize recent increases in brand-name drug prices

The Wall Street Journal: "Reports of prescription drug-price increases have congressional Democrats complaining about price gouging and questioning whether drug companies are reneging on a pledge to provide billions of savings as part of a U.S. health-care overhaul sought by President Barack Obama.

8 Dec 2009

Reuters news examines quest for new TB drugs, vaccines

Reuters examines the search for new tuberculosis medicines and vaccines. "Although TB has plagued humankind for thousands of years, there is only one vaccine," which isn't very effective and doesn't protect adults. "With the exception of rifabutin, there has been no new drug for TB for more than 40 years," the news service writes.

8 Dec 2009

CSL Behring selects BioRx as an approved Berinert provider

BioRx, a specialty pharmacy company, has been named one of a small number of approved providers of Berinert®. Berinert® is a plasma-derived concentrate of C1 esterase inhibitor (human) indicated for the treatment of acute abdominal or facial attacks of hereditary angioedema (HAE) in adult and adolescent patients. CSL Behring, the manufacturer of Berinert® selected BioRx as part of their distribution network to launch this exciting new product in the United States.

8 Dec 2009

Brazil: The largest emerging pharmaceutical market for hepatitis C virus

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that at approximately $120 million, the hepatitis C virus drug market in Brazil is among the largest emerging pharmaceutical markets for the disease.

8 Dec 2009

Arcadia Biosciences' SONOVA 400 receives FDA approval as a dietary supplement ingredient

Arcadia Biosciences, Inc., an agricultural technology company focused on developing technologies and products that benefit the environment and human health, announced today that it has successfully completed the U.S. Food and Drug Administration (FDA) regulatory process for SONOVA™ 400.

8 Dec 2009

BARDA cancels PharmAthene's RFP for Recombinant Protective Antigen Anthrax Vaccine

PharmAthene, Inc. a biodefense company specializing in the development and commercialization of medical countermeasures against chemical and biological threats, announced today that the Department of Health and Human Services Biomedical Research and Development Authority (BARDA) has canceled its request for proposal (RFP) for Recombinant Protective Antigen Anthrax Vaccine for the Strategic National Stockpile (RFP BARDA 08-15).

8 Dec 2009

Pixantrone demonstrates substantial reduction in cardiac cell toxicity compared to anthracyclines

Cell Therapeutics, Inc. announced today an abstract to be published online at the journal Blood website by M. Hacker, et al. demonstrating significant reduction in cardiac cell toxicity with pixantrone compared to currently marketed anthracyclines. The authors conclude that the reduction is due to pixantrone's inability to generate toxic drug iron complexes and reduced propensity to generate oxygen free radicals.

8 Dec 2009

ASH meeting highlights H1N1 pandemic threat, new trends and treatment options for children with genetic blood disorder

Sickle cell disease, a condition characterized by deformed and dysfunctional red blood cells, is one of the most common genetic blood disorders affecting millions of people around the world, including more than 70,000 Americans (National Heart, Lung, and Blood Institute.

8 Dec 2009

Department of Health reminds at-risk Pennsylvanians to receive H1N1 vaccination

The federal Centers for Disease Control and Prevention, or CDC, has allocated a total of 2,940,300 doses of H1N1 flu vaccine to Pennsylvania to date, the state Department of Health said today.

8 Dec 2009

Erbitux gaining market share of Avastin in Europe

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite its dominance in early lines of metastatic colorectal cancer treatment, Roche/Chugai's Avastin will face increasing competition from Bristol-Myers Squibb/Eli Lilly/Merck KGaA's Erbitux in Germany, France and Spain.

8 Dec 2009

CML patients on nilotinib or dasatinib drug achieve better response than imatinib drug

Two medications approved as treatment for drug-resistant chronic myeloid leukemia continue to provide patients with quicker, better responses as a first treatment than the existing front-line drug, researchers at The University of Texas M. D. Anderson Cancer Center reported at the 51st Annual Meeting of the American Society of Hematology.

8 Dec 2009

Results of two new studies support the use of intravenous Vimpat for patients in clinical settings

Results of two new studies support the use of the intravenous formulation of the antiepileptic drug (AED) Vimpat® for patients requiring add-on therapy in clinical settings where oral AED therapy is temporarily not feasible.

8 Dec 2009

CeNeRx BioPharma's TriRima reversibly inhibits MAO-A, confirms PET imaging study

CeNeRx BioPharma, Inc., a clinical stage company developing innovative treatments for diseases of the central nervous system, today announced that a newly published PET imaging study in human subjects confirms that CeNeRx's novel compound TriRima(TM) reversibly inhibits MAO-A (monoamine oxidase A), an enzyme in the brain that plays a key role in the regulation of mood.

8 Dec 2009

Specialty pharmaceutical market: Treatment patterns and product performance

IMS Health, the world’s leading provider of market intelligence to the pharmaceutical and healthcare industries, today announced the wide-scale availability of its advanced analytical offering, IMS Specialty Market Dynamics™, which delivers the most complete view of treatment patterns and product performance in the rapidly growing specialty pharmaceutical market.

8 Dec 2009

Generic erosion of premium-priced branded agents to offset sales of new agents

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that generic erosion of premium-priced branded agents will offset sales of new agents and will cause the acute coronary syndrome market for drugs in the hospital setting to decrease from $800 million in 2008 to $729 million in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

8 Dec 2009

Market for personalized medicine in the United States to grow 11 percent annually, shows report

The market for personalized medicine in the United States is already $232 billion, and it is projected to grow 11 percent annually, according to a new report published today by PricewaterhouseCoopers LLP, entitled The Science of Personalized Medicine: Translating the Promise into Practice.

8 Dec 2009

Pharmaceutical News

Macomb County Health Department opens new H1N1 influenza immunization clinics

Neuroscientists suggest risky therapy for aging brain may be avoidable by focusing on hormone target

Scientists identify new potential drug for treating acute myeloid leukaemia

CDC awards $19.7 million contract to study new drugs for tuberculosis treatment

House Democrats criticize recent increases in brand-name drug prices

Reuters news examines quest for new TB drugs, vaccines

CSL Behring selects BioRx as an approved Berinert provider

Brazil: The largest emerging pharmaceutical market for hepatitis C virus

Arcadia Biosciences' SONOVA 400 receives FDA approval as a dietary supplement ingredient

BARDA cancels PharmAthene's RFP for Recombinant Protective Antigen Anthrax Vaccine

Pixantrone demonstrates substantial reduction in cardiac cell toxicity compared to anthracyclines

ASH meeting highlights H1N1 pandemic threat, new trends and treatment options for children with genetic blood disorder

Department of Health reminds at-risk Pennsylvanians to receive H1N1 vaccination

Erbitux gaining market share of Avastin in Europe

CML patients on nilotinib or dasatinib drug achieve better response than imatinib drug

Results of two new studies support the use of intravenous Vimpat for patients in clinical settings

CeNeRx BioPharma's TriRima reversibly inhibits MAO-A, confirms PET imaging study

Specialty pharmaceutical market: Treatment patterns and product performance

Generic erosion of premium-priced branded agents to offset sales of new agents

Market for personalized medicine in the United States to grow 11 percent annually, shows report

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News